Please check your internet connection and try again.
# Sompraz HP (Esomeprazole Magnesium)
## Overview
Sompraz HP is a combination product containing esomeprazole magnesium, a proton pump inhibitor (PPI), and amoxicillin and clarithromycin, antibiotics. It is used for the eradication of *Helicobacter pylori* (H. pylori) infection in patients with peptic ulcer disease.
## Primary Indications
Eradication of *Helicobacter pylori* infection in patients with duodenal ulcer disease, gastric ulcer disease, or a history of both.
## Adult Dosing
The standard adult dose is one (1) packet twice daily for 10-14 days. Each packet contains:
* Esomeprazole 20 mg
* Amoxicillin 1000 mg
* Clarithromycin 500 mg
*Note: Dosing duration and specific regimen may vary based on local resistance patterns and clinical guidelines. It is essential to consult current prescribing information or local protocols for definitive guidance.*
## Pediatric Dosing
Pediatric dosing for Sompraz HP is not established.
## Dose Adjustments
No specific dose adjustments are recommended for patients with renal or hepatic impairment, however, caution should be exercised. Patients with severe renal impairment may require closer monitoring. For hepatic impairment, the maximum daily dose of esomeprazole should not exceed 20 mg.
## Contraindications
* Known hypersensitivity to esomeprazole, amoxicillin, clarithromycin, or any component of the formulation.
* History of severe hypersensitivity reactions to other beta-lactam antibacterial drugs (e.g., penicillin, cephalosporins).
* History of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use.
* Concomitant use with ritonavir-boosted protease inhibitors (e.g., atazanavir, nelfinavir) due to potential for serious adverse events.
* Patients with known or suspected QT prolongation or ventricular arrhythmia.
* Use in patients with electrolyte abnormalities (hypokalemia, hypomagnesemia).
## Adverse Effects
Common adverse effects include:
* Diarrhea
* Abdominal pain
* Nausea
* Headache
* Dysgeusia (altered taste)
* Rash
Serious adverse effects may include:
* Hypersensitivity reactions (including anaphylaxis)
* Clostridioides difficile-associated diarrhea (CDAD)
* QT prolongation and ventricular arrhythmias
* Hepatotoxicity
* Renal impairment
* *Stevens-Johnson syndrome/toxic epidermal necrolysis*
## Key Drug Interactions
* **Warfarin:** Increased INR and prothrombin time. Monitor INR closely.
* **Clopidogrel:** Clarithromycin may inhibit CYP2C19, potentially reducing the efficacy of clopidogrel.
* **CYP3A4 Substrates:** Clarithromycin is a moderate inhibitor of CYP3A4. Concomitant use with drugs metabolized by CYP3A4 (e.g., statins, calcium channel blockers, benzodiazepines) may increase plasma concentrations and risk of toxicity.
* **Antacids/Sucralfate:** May decrease absorption of esomeprazole. Administer esomeprazole at least 1 hour before antacids or sucralfate.
* **Methotrexate:** PPIs can increase levels of methotrexate. Consider temporary discontinuation of PPI or dose reduction of methotrexate.
## Monitoring
* Monitor for signs and symptoms of hypersensitivity reactions.
* Assess for and treat diarrhea promptly; rule out C. difficile infection.
* Monitor electrolytes, especially in patients with pre-existing conditions or receiving other drugs that can affect electrolyte levels.
* Monitor renal and hepatic function, particularly in patients with impaired function.
* If used concurrently with warfarin, monitor INR.
## Clinical Pearls
* Sompraz HP is a fixed-dose combination; individual components cannot be adjusted. If dose modification is needed, separate agents may be required.
* Ensure adequate duration of therapy for H. pylori eradication.
* Patient education on completing the full course of antibiotics is crucial.
* Consider potential for cross-reactivity with penicillin allergies.
***
*Disclaimer: This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and local protocols for definitive guidance before initiating treatment. Drug information is subject to change.*
